Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Anebulo Pharmaceuticals Inc (ANEB)

Anebulo Pharmaceuticals Inc (ANEB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 41,601
  • Shares Outstanding, K 40,785
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,480 K
  • EBIT $ -9 M
  • EBITDA $ -9 M
  • 60-Month Beta -0.69
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.73
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.19
  • Most Recent Earnings $-0.05 on 02/12/26
  • Next Earnings Date 05/12/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.05
  • Growth Rate Est. (year over year) +1,998,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2999 +243.45%
on 03/03/26
1.1200 -8.04%
on 03/18/26
+0.5984 (+138.65%)
since 02/24/26
3-Month
0.2999 +243.45%
on 03/03/26
1.2500 -17.60%
on 12/26/25
-0.1700 (-14.17%)
since 12/24/25
52-Week
0.2999 +243.45%
on 03/03/26
3.4200 -69.88%
on 07/23/25
-0.5500 (-34.81%)
since 03/24/25

Most Recent Stories

More News
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company”...

ANEB : 1.0300 (+0.98%)
Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company”...

ANEB : 1.0300 (+0.98%)
Anebulo Pharmaceuticals Announces Final Results of Tender Offer

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company”...

ANEB : 1.0300 (+0.98%)
Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company”...

ANEB : 1.0300 (+0.98%)
Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company”...

ANEB : 1.0300 (+0.98%)
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company”...

ANEB : 1.0300 (+0.98%)
Anebulo Pharmaceuticals’ Bold Move: Potential Risks of Going Private with Reverse Stock Split

Anebulo Pharmaceuticals, Inc. (ANEB) has disclosed a new risk, in the Share Price & Shareholder Rights category.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful...

ANEB : 1.0300 (+0.98%)
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company”...

ANEB : 1.0300 (+0.98%)
Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the “Company”...

ANEB : 1.0300 (+0.98%)
Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the “Company”...

ANEB : 1.0300 (+0.98%)

Business Summary

Anebulo Pharmaceuticals Inc. is a clinical-stage biotechnology company. It involved in developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The company's product candidate includes ANEB-001. Anebulo Pharmaceuticals Inc. is based in Texas, United States.

See More

Key Turning Points

3rd Resistance Point 1.0900
2nd Resistance Point 1.0700
1st Resistance Point 1.0500
Last Price 1.0300
1st Support Level 1.0100
2nd Support Level 0.9900
3rd Support Level 0.9700

See More

52-Week High 3.4200
Fibonacci 61.8% 2.2281
Fibonacci 50% 1.8600
Fibonacci 38.2% 1.4918
Last Price 1.0300
52-Week Low 0.2999

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.